Latest News - Bonti

Wednesday, September 19, 2018 | Acquisitions and Mergers,, Product Launches and Updates, Allergan , Bonti

Special Report: Behind Allergan’s and Bonti’s Headline-Making Deal

The race was on. After years of dormancy in the neuromodulator category, at least three novel toxins -- Evolus’ DWP-450, Revance’s daxibotulinumtoxinA, and Bonti’s EB-001 -- were co…

Read the full story

Friday, September 14, 2018 | Acquisitions and Mergers,, Allergan , Bonti

Allergan Acquires Bonti for $195M

Allergan acquired Bonti, Inc., a privately held clinical-stage biotechnology company focused on the development and commercialization of novel, fast-acting neurotoxin programs for aesthetic and therap…

Read the full story

Thursday, August 02, 2018 | Personnel/Company News,, Research and Publications, Bonti

Bonti’s Novel Neurotoxin Shows Promise in Early Study of Scar Reduction After Mohs Surgery

Topline results from Bonti’s SHINE-1 Phase 2a clinical trial suggest that its novel neurotoxin is safe and likely effective for scar reduction following Mohs surgery. EB-001, the active ingre…

Read the full story

Monday, February 12, 2018 | Personnel/Company News,, Bonti

Jacob Chacko, MD Joins Bonti’s Board of Directors

Jacob Chacko, MD has joined Bonti’s Board of Directors. Dr. Chacko has served as the Chief Financial Officer of Ignyta, Inc. since May 2014. At Ignyta, he leads multiple functions, …

Read the full story